Studies at IDWeek 2021 show that pneumococcal vaccines with increased serotype valency are safe and efficacious in both children and adults. Here is my take on how these studies could affect my practice and the current vaccination guidelines.
Listen to expert insights from Martin C. Mahoney, MD, PhD, on new data for vaccine-preventable diseases presented at the IDWeek meeting, including pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.
In this downloadable slideset, CCO’s expert faculty summarizes important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.
Hear unique insights from expert faculty on important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.